Wednesday, October 4, 2023
SUBSCRIBE
Wednesday, October 4, 2023

Contact: 561.316.3330

SUBSCRIBE
Search
HomeIMAGING

Envista Announces DEXIS Brand Name for Imaging Business

DEXIS: Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced Envista’s KaVo imaging business will be re-branded as “DEXIS”.

Dental professionals have known the DEXIS brand as the leader in digital intraoral radiography and diagnostic software innovation for over 20 years. The DEXIS brand will now represent a full portfolio of award-winning imaging and digital solutions including cone-beam computed tomography (CBCT), handheld x-rays, intraoral scanners, sensors, and navigated surgical solutions.

DEXIS will combine other leading brands including i-CAT, Gendex, Instrumentarium, SOREDEX, and NOMAD, which with DEXIS are pioneers in x-ray generation, digital intraoral radiography, panoramic and cephalometric imaging, and 3D CBCT imaging. We have one of the largest installed bases of dental imaging devices in the industry with over 150,000 imaging devices currently utilized in dental practices. End-users of imaging devices can utilize our new diagnostics and treatment planning software suite DTX Studio to access all clinical patient images in one place, using one software.

Envista Holdings Corporation CEO Amir Aghdaei said, “We are excited to unite our imaging portfolio under the DEXIS brand and unveil our new DEXIS logo that will be featured on our entire imaging portfolio. This is one step in our continued efforts to create integrated, digital workflows that connect all our products and enable dental professionals to treat and improve more patient lives. We are living out our strategy to digitize, personalize, and democratize dentistry and look forward to the future.”

Headquartered in the United States, DEXIS is present in over 50 countries and has a workforce of approximately 1,000 employees. Over the rest of 2022, the imaging portfolio will transition in branding from KaVo to DEXIS with different schedules by product and by region. DEXIS continues to value its distributor partnerships and is excited to partner with distributors around the world to bring end-to-end, digital, diagnostic workflow solutions to dental professionals.

SourceEnvista Holdings Corporation
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).
Read more

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.
Read more

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.
Read more

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.
Read more

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."
Read more

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy